ARTHROPLASTY
TKA: Epoetin alfa leads to improved hematological parameters and lower risk of transfusion
J Arthroplasty. 2006 Aug;21(5):628-3550 patients with pretreatment hemoglobin level of 100 to 130 g/L who were undergoing primary total knee reconstruction were randomized to receive standard care using preoperative autologous blood donation (PAD) or recombinant human erythropoietin (epoetin alfa) at 40 000 U (preoperative day 14). Blood counts were done every day for up to 5 days after the operation. From the day of surgery to two days post-operatively, the epoetin alfa group had significantly higher hemoglobin, hematocrit and reticulocyte counts than the PAD group. There was no difference between the two groups for the number of patients requiring a post-operative allogeneic blood transfusion or for the rate of adverse events.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
